Abstract
In Lynch syndrome surveillance aims at prevention of early detection of cancer types observed to occur in significant excess. At present, regular prophylactic examinations have been shown beneficial for colorectal and endometrial cancer, i.e. repeated colonoscopy and endometrial biopsy combined with ultrasonograpy. For other less common cancer types involved, no proven benefit has been shown. The guidelines of identifying Lynch syndrome, the principles of genetic testing, and arranging surveillance are reviewed in this article, also shortly dealing with prophylactic surgery and possible chemoprevention in future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020–7.
Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6:105–10.
Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214–8.
Wilson JMG, Junger G. Principles and practice of screening for disease. Public Health Papers 34. WHO, Geneva; 1968
Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193–200.
Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986–94.
Vasen HF, Watson P, Mecklin J-P, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1999;116:1453–6.
Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.
Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354:271–2763.
Engel C, Forberg C, Holinski-Feder E, et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer. 2006;118:115–22.
Lerman G, Hughes C, Trock B, et al. Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA. 1999;281:1618–22.
Aktán-Collán K, Mecklin J-P, Järvinen HJ, et al. Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer. 2000;89:44–50.
Pylvänäinen K, Kairaluoma M, Mecklin J-P. Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Fam Cancer. 2006;5:175–8.
Jass JR, Stewart SM, Lane MR. Hereditary non-polyposis colorectal cancer – morphologies, genes and mutations. Mutat Res. 1994;310:125–33.
Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet. 2005;42:491–6.
Mecklin J-P, Järvinen HJ, Peltokallio P. Cancer family syndrome. Genetic analysis of 22 Finnish kindreds. Gastroenterology. 1986;90:328–33.
Aarnio M, Mecklin J-P, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64:430–3.
de Jong AE, Nagengast FM, Kleibeuker JH, et al. What is the appropriate screening protocol in Lynch syndrome? Fam Cancer. 2006;5:373–8.
Renkonen-Sinisalo L, Aarnio M, Mecklin J-P, et al. Surveillance improves survival on colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev. 2000;24:137–42.
de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum. 2002;45:1588–94.
Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.
Renkonen-Sinisalo L, Kivisaari A, Kivisaari L, et al. Utility of computed tomographic colonography in surveillance for hereditary nonpolyposis colorectal cancer syndrome. Fam Cancer. 2007;6:135–40.
Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet. 1999;23:142–4.
Dove-Edvin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer. 2002;94:1708–12.
Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2003;91:74–80.
Renkonen-Sinisalo L, Bützow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer. 2007;120:821–4.
Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol. 2002;37:574–7.
Myrhoj T, Andersen M-B, Bernstein I. Screening for urinary tract cancer with urine cytology in HNPCC-families. Fam Cancer. 2007;6:346 (abstr).
Church JM. Prophylactic colectomy in patients with hereditary non-polyposis colorectal cancer. Ann Med. 1996;28:479–82.
Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–9.
Sandler RS, Halabi S, Baron JB. A randomized trial of aspirin to prevent colorectal adenomas with previous colorectal cancer. N Engl J Med. 2003;348:883–90.
Steinbach GD, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52.
Lu K, Loose D, Lynch H, et al. Preliminary analysis of a prospective, multi-center endometrial cancer chemoprevention study in women with Lynch syndrome. Fam Cancer. 2007;6:347 (abstr).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Järvinen, H.J., Mecklin, JP. (2010). Surveillance. In: Rodriguez-Bigas, M., Cutait, R., Lynch, P., Tomlinson, I., Vasen, H. (eds) Hereditary Colorectal Cancer. M.D. Anderson Solid Tumor Oncology Series, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-6603-2_18
Download citation
DOI: https://doi.org/10.1007/978-1-4419-6603-2_18
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-6602-5
Online ISBN: 978-1-4419-6603-2
eBook Packages: MedicineMedicine (R0)